

METASTATIC COLORECTAL CANCER

Personalized TumorGraft™ case study: 44-year-old female diagnosed with metastatic colorectal cancer who had 3 prior regimens¹


First line: FOLFOX (5-Fluorouracil, Leucovorin, Oxaliplatin) plus Bevacizumab (Avastin);

Second line: FOLFORI (5-Fluorouracil, Leucovorin, Irinotecan);

Third line: Cetuximab monotherapy

PERSONALIZED TUMORGRAFT™ RESPONSE TO DRUG TESTING


First round of drug testing (fourth line of treatment)




1. Patient's pelvic tumor regressed by 60% following Irinotecan monotherapy (partial response)
 - The patient had resolution of the hydronephrosis
 - Patient remained in partial response for >50 months
2. Additional drug testing revealed that maximal response in the patient's Personalized TumorGraft™ was achieved with Laptinib combined with Xeloda (fifth line of treatment)
 - Patient's tumor regressed (partial response) for 6 more months

¹Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, et al. A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther June 2011.

RESPONSE TO FOURTH-LINE TREATMENT



Further investigations: second response to Irinotecan therapy



Case study conclusion

- The Personalized TumorGraft™ revealed that the patient would respond best to one of the three combined treatments she received previously
- Patient responded to two courses of Champions-guided treatment
- The patient would have likely never received Irinotecan again if not for Personalized TumorGraft™ testing



Personalized Oncology Solutions

Champions Oncology, Inc.
One University Plaza, Suite 307
Hackensack, NJ 07604
Phone: 201.808.8400

www.ChampionsOncology.com